Product Data Sheet

Alexa Fluor® 647 anti-BrdU

2420535 / 25 tests Catalog # /

Size: 2420540 / 100 tests

Clone: 3D4

Isotype: Mouse IgG1, ĸ

Iodouridine-conjugated ovalbumin Immunogen:

Preparation: The antibody was purified by affinity

> chromatography and conjugated with Alexa Fluor® 647 under optimal


conditions.

Formulation: Phosphate-buffered solution, pH 7.2,

containing 0.09% sodium azide and

BSA (origin USA).

Lot-specific Concentration:



HEL cell line was pulsed with BrdU for 1 hour (upper panel) or without (lower panel) and then stained with anti-BrdU (3D4) Alexa Fluor® 647 according to BioLegend BrdU staining procedure. Cells were subsequently stained with 1 µg of DAPI for DNA analysis.

Applications:

Applications: Immunohistochemistry, Intracellular

Staining for Flow Cytometry

Recommended **Usage:**

Each lot of this antibody is quality control tested by intracellular

immunofluorescent staining with flow

cytometric analysis. For flow

cytometric staining, the suggested use of this reagent is 5 µl per million cells or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for

each application.

* Alexa Fluor® 647 has a maximum emission of 668 nm when it is excited

at 633 nm / 635 nm.

Application Notes: Additional reported applications (for

the relevant formats) include: immunohistochemistry and fluorescence microscopy.


Application References:

1. Dolbeare F, et al. 1983. Proc. Natl. Acad. Sci. USA 80:5573.

2. Hirota K, et al. 2007. J. Exp. Med. 204:41.

3. Godebu E, et al. 2008. J. Immunol. 181:1798.

4. Waskow C. et al. 2008, Nat. Immunol, 9:676.



Description: BrdU is a uridine derivative and a structural analog of thymidine, which can be

incorporated into DNA during the S-phase of a cell cycle as a substitute for thymidine. Cells can be pulse-labeled with BrdU and analyzed with antibodies against BrdU to determine the proportion of cells in the S-phase of the cell

cycle during a given interval.

Antigen References:

1. Barker JM, et al. 2013. PLoS One 8:e63692.

2. Duque A and Rakic P. 2011. *J. Neurosci.* 31:15205.

3. Robbins S, et al. 2011. J. Vis. Exp. 55:2855.

4. Broekhuizen CA, et al. 2010. Infect Immun. 78:954.

5. van der Wath RC, et al. 2009. PLoS One 4:e6972.

6. Dolbeare F, et al. 1985. Cytometry 6:521.

7. Gratzner HG. 1982. Science 218:474.